Skip to main content

Dr. Stephen T. Oh, MD

Hematology (Hematology (Internal Medicine) Physician)

  • Medicare participating

At a glance

Years since graduation
22
In the NPI registry since
2007
Medicare patients seen, 2024
80

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2004Medical school: Northwestern University Feinberg Medical School
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology (Internal Medicine) Physician primary
    MO license 2010042897

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
80
Services billed
2,968
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Insertion of needle into vein for collection of blood sample12152
Established patient office or other outpatient visit, 30-39 minutes3828
Injection of drug or substance under skin or into muscle1918
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less1814
Administration of chemotherapy into vein, 1 hour or less1515

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Jakafi (ruxolitinib phosphate)236
Hydroxyurea
Other prescribers in Saint Louis, MO
124
Ojjaara (momelotinib dihydrochloride)28
Anagrelide Hcl26
Ayvakit (avapritinib)24
Besremi (ropeginterferon alfa-2b-njft)17
Tasigna (nilotinib hcl)14
Ondansetron Odt (ondansetron)
Other prescribers in Saint Louis, MO
14
Allopurinol
Other prescribers in Saint Louis, MO
11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 40 payments worth $34,444 in total to this clinician.

By company
Takeda Pharmaceuticals U.S.A., Inc.$15,711
Incyte Corporation$11,623
Pharmaessentia USA Corporation$6,888
GlaxoSmithKline, LLC.$88.65
Sobi, Inc$73.58
Novo Nordisk Inc$24.53
Servier Pharmaceuticals LLC$20.29
Hema Biologics, LLC$15.04
By type
Consulting Fee$31,614
Travel and Lodging$1,923
Food and Beverage$899
Education$8.01

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 28, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 28, 2025
Consulting Fee$11,880
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Consulting Fee$9,590
Oct 21, 2025Pharmaessentia USA Corporation
Oct 21, 2025
Consulting Fee
BESREMI · Oncology
$6,664
Jun 30, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jun 30, 2025
Consulting Fee$3,080
Jul 28, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 28, 2025
Travel and Lodging
travel to CHICAGO, IL · in-kind
$406
May 9, 2025Incyte Corporation
May 9, 2025
Consulting Fee$400
Dec 6, 2025Incyte Corporation
Dec 6, 2025
Travel and Lodging
Jakafi · Hematology/Oncology · travel to Orlando, FL
$331
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Travel and Lodging
travel to Irving, TX
$304
Apr 9, 2025Incyte Corporation
Apr 9, 2025
Travel and Lodging
travel to Irving, TX
$242
Oct 21, 2025Pharmaessentia USA Corporation
Oct 21, 2025
Travel and Lodging
BESREMI · Oncology · travel to Chicago, IL
$194
All 18 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 11, 2025Takeda Pharmaceuticals U.S.A., Inc.
Dec 11, 2025
Education
in-kind
$8.01
Dec 6, 2025Incyte Corporation
Dec 6, 2025
Travel and Lodging
Jakafi · Hematology/Oncology · travel to Orlando, FL
$331
Oct 21, 2025Pharmaessentia USA Corporation
Oct 21, 2025
Consulting Fee
BESREMI · Oncology
$6,664
Oct 21, 2025Pharmaessentia USA Corporation
Oct 21, 2025
Travel and Lodging
BESREMI · Oncology · travel to Chicago, IL
$194
Jul 28, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 28, 2025
Consulting Fee$11,880
Jul 28, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 28, 2025
Travel and Lodging
travel to CHICAGO, IL · in-kind
$406
Jul 28, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 28, 2025
Travel and Lodging
travel to CHICAGO, IL · in-kind
$40.28
Jul 28, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 28, 2025
Travel and Lodging
travel to CHICAGO, IL · in-kind
$8.00
Jun 30, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jun 30, 2025
Consulting Fee$3,080
Jun 30, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jun 30, 2025
Travel and Lodging
travel to MILAN, Italy · in-kind
$85.48
May 9, 2025Incyte Corporation
May 9, 2025
Consulting Fee$400
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Consulting Fee$9,590
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Travel and Lodging
travel to Irving, TX
$304
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Travel and Lodging
travel to Irving, TX
$125
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Travel and Lodging
travel to Irving, TX
$51.88
Apr 10, 2025Incyte Corporation
Apr 10, 2025
Travel and Lodging
travel to Irving, TX
$25.00
Apr 9, 2025Incyte Corporation
Apr 9, 2025
Travel and Lodging
travel to Irving, TX
$242
Apr 9, 2025Incyte Corporation
Apr 9, 2025
Travel and Lodging
travel to Irving, TX
$110

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 15 industry-funded studies in 2025, from 6 companies. The companies reported $1,114,142 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms
    Incyte Corporation
  • Study name not reported
    Pharmaessentia USA Corporation
  • A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI0610 with and without Ruxo…
    Novartis Pharmaceuticals Corporation
  • A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
    Novartis Pharmaceuticals Corporation
  • Study name not reported
    Pharmaessentia USA Corporation
  • This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants wit…
    Incyte Corporation
  • A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis
    Incyte Corporation
  • Study name not reported
    Incyte Corporation
  • Study name not reported
    Pharmaessentia USA Corporation
  • (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
    Blueprint Medicines Corporation · Active, not recruiting · NCT03731260

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1841494358. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.